

Part VI: Summary of the risk management plan

Summary of risk management plan for Eltrombopag KRKA 25 mg, 50 mg and 75 mg film coated tablets (eltrombopag)

This is a summary of the risk management plan (RMP) for Eltrombopag KRKA 25 mg, 50 mg and 75 mg film coated tablets (hereafter referred to as Eltrombopag by Krka). The RMP details important risks of Eltrombopag by Krka, how these risks can be minimised and how more information will be obtained about Eltrombopag by Krka's risks and uncertainties (missing information).

Eltrombopag by Krka's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Eltrombopag by Krka should be used.

Important new concerns or changes to the current ones will be included in updates of Eltrombopag by Krka's RMP.

I. The medicine and what it is used for

Eltrombopag by Krka is authorised for immune thrombocytopenia, chronic hepatitis C -associated thrombocytopenia and severe aplastic anaemia (see SmPC for the full indication). It contains eltrombopag as the active substance and it is given orally.

II. Risks associated with the medicine and activities to minimise or further characterise the risks

Important risks of Eltrombopag by Krka, together with measures to minimise such risks and the proposed studies for learning more about Eltrombopag by Krka's risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of Eltrombopag by Krka is not yet available, it is listed under 'missing information' below.

II.A List of important risks and missing information

Important risks of Eltrombopag by Krka are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Eltrombopag by Krka. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

List of important risks and missing information	
Important identified risks	<p>Adult ITP, Paediatric ITP, HCV-associated thrombocytopenia and severe aplastic anaemia</p> <ul style="list-style-type: none"> • Hepatotoxicity • Thromboembolic events <p>HCV-associated thrombocytopenia</p> <ul style="list-style-type: none"> • Hepatic decompensation
Important potential risks	<p>Adult ITP, Paediatric ITP, and HCV-associated thrombocytopenia and severe aplastic anaemia</p> <ul style="list-style-type: none"> • Increased Bone Marrow Reticulin Formation • Haematological malignancies <p>Severe aplastic anaemia</p> <ul style="list-style-type: none"> • Cytogenetic abnormalities
Missing information	<p>Adult ITP, Paediatric ITP, and HCV-associated thrombocytopenia and severe aplastic anaemia</p> <ul style="list-style-type: none"> • Patients with hepatic impairment <p>Severe aplastic anaemia</p> <ul style="list-style-type: none"> • Use in paediatric population

II.B Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-authorisation development plan

II.C.1 Studies which are conditions of the marketing authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Eltrombopag by Krka.

II.C.2 Other studies in post-authorisation development plan

There are no studies required for Eltrombopag by Krka.